Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 6/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24630999 | 0.95 | SIGMAR1 (0.38) | KDM4EHTR1AADRB1ADRB2SIGMAR1 | |
| SCHEMBL24630996 | 0.85 | LMNA (0.40) | KDM4EHTR1AADRB1ADRB2SIGMAR1 | |
| SCHEMBL24630918 | 0.81 | ADRB1 (0.47) | ADRB1ADRB2 | |
| SCHEMBL24630979 | 0.80 | SIGMAR1 (0.40) | KDM4EHTR1AADRB1ADRB2SIGMAR1 | |
| SCHEMBL24631010 | 0.78 | ADRB1 (0.33) | ADRB1ADRB2 | |
| SCHEMBL22864107 | 0.78 | ADRB2 (0.48) | KDM4EADRB1ADRB2LMNA | |
| SCHEMBL24630994 | 0.78 | ADRB2 (0.36) | KDM4EADRB1ADRB2 | |
| SCHEMBL24630929 | 0.77 | ADRB1 (0.34) | ADRB1ADRB2 | |
| SCHEMBL24631035 | 0.75 | ADRB2 (0.36) | ADRB1ADRB2 | |
| SCHEMBL6925470 | 0.70 | GLA (0.46) | KDM4EADRB1ADRB2SIGMAR1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2021003161-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | KDM4E 4707/4885HTR1A 154/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.